ARSU.F Stock Overview

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. More details

ARSU.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	5/6
Financial Health	4/6
Dividends	3/6

Rewards

Trading at 66.1% below our estimate of its fair value

Earnings are forecast to grow 13.68% per year

Earnings grew by 15.5% over the past year

Risk Analysis

Shares are highly illiquid

Unstable dividend track record

Has a high level of debt

My Notes

Capture your thoughts, links and company narrative

Fagron NV Competitors

Patterson Companies

NasdaqGS:PDCO

US$2.7b

Henry Schein

NasdaqGS:HSIC

US$8.7b

Cardinal Health

NYSE:CAH

US$28.8b

Cencora

NYSE:COR

US$44.0b

Price History & Performance

Summary of share price highs, lows and changes for Fagron
Historical stock prices
Current Share Price	€20.03
52 Week High	€20.85
52 Week Low	€18.06
Beta	0.25
1 Month Change	0%
3 Month Change	n/a
1 Year Change	8.39%
3 Year Change	28.83%
5 Year Change	-2.10%
Change since IPO	-63.29%

Recent updates

Shareholder Returns

	ARSU.F	US Healthcare	US Market
7D	0%	3.3%	2.8%
1Y	8.4%	-9.1%	24.6%

Return vs Industry: ARSU.F exceeded the US Healthcare industry which returned -9.8% over the past year.

Return vs Market: ARSU.F underperformed the US Market which returned 24.5% over the past year.

Price Volatility

Is ARSU.F's price volatile compared to industry and market?
ARSU.F volatility
ARSU.F Average Weekly Movement	n/a
Healthcare Industry Average Movement	7.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ARSU.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ARSU.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1990	3,647	Rafael Padilla	www.fagron.com

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.

Fagron NV Fundamentals Summary

How do Fagron's earnings and revenue compare to its market cap?
ARSU.F fundamental statistics
Market cap	US$1.27b
Earnings (TTM)	US$81.22m
Revenue (TTM)	US$855.32m

15.6x

P/E Ratio

1.5x

P/S Ratio

Is ARSU.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARSU.F income statement (TTM)
Revenue	€820.76m
Cost of Revenue	€458.22m
Gross Profit	€362.54m
Other Expenses	€284.61m
Earnings	€77.94m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.07
Gross Margin	44.17%
Net Profit Margin	9.50%
Debt/Equity Ratio	69.2%

How did ARSU.F perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

28%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 13:26
End of Day Share Price	2024/10/29 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fagron NV is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Jan Vos	ABN AMRO Bank N.V.
Marc Leemans	Banque Degroof
Victoria Lambert	Berenberg